S&P Futures
3,929.25 +31.50 (+0.81%) Dow Futures
31,402.00 +200.00 (+0.64%) Nasdaq Futures
12,007.50 +129.25 (+1.09%) Russell 2000 Futures
1,792.90 +18.00 (+1.01%) Crude Oil
110.85 -1.36 (-1.21%) Gold
1,841.60 +0.40 (+0.02%)
Global Blood Therapeutics, Inc. (GBT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 27.04 |
| Open | 26.98 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 25.85 - 27.65 |
| 52 Week Range | 22.67 - 41.73 |
| Volume | |
| Avg. Volume | 1,193,808 |
| Market Cap | 1.747B |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.86 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.63 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GBT
Related Research
- Global Blood Therapeutics, Inc.QURE: What does Argus have to say about QURE?UNIQURE NV has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat2 days agoArgus Research
- GlobeNewswire
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an
- Simply Wall St.
Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
- Motley Fool
Why Global Blood Therapeutics Stock Was Sickly Today
For the quarter, Global Blood Therapeutics' sales hit nearly $55.2 million, representing quite an encouraging improvement over the year-ago quarter's $39 million. Although the revenue figure didn't quite reach the $56.1 million analysts were collectively estimating, Global Blood Therapeutics beat on the bottom line. Global Blood Therapeutics also launched the drug for patients aged 4 to 11.
